Magnetic Resonance Imaging of the Neuroprotective Effect of Xaliproden in Rats
Autor: | Laurent Lemaire, Peter Keane, Jacqueline Fournier, Jean Vion-Dury, Sylviane Confort-Gouny, Yann Le Fur, Christian Ponthus, Patrick J. Cozzone |
---|---|
Přispěvatelé: | Micro et Nanomédecines Translationnelles (MINT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre de résonance magnétique biologique et médicale (CRMBM), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS) |
Rok vydání: | 2002 |
Předmět: |
Male
Time Factors [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging Pyridines MESH: Rats Sprague-Dawley MESH: Magnetic Resonance Imaging Rats Sprague-Dawley chemistry.chemical_compound 0302 clinical medicine Hippocampus (mythology) MESH: Animals Enzyme Inhibitors MESH: Choline O-Acetyltransferase 0303 health sciences medicine.diagnostic_test Brain MESH: Naphthalenes MESH: Neuroprotective Agents General Medicine Magnetic Resonance Imaging Vincristine Injection Neuroprotective Agents MESH: Enzyme Inhibitors Vincristine Anesthesia medicine.drug MESH: Rats MESH: Vincristine Naphthalenes Neuroprotection Choline O-Acetyltransferase MESH: Brain 03 medical and health sciences [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication Alzheimer Disease medicine Animals Radiology Nuclear Medicine and imaging Xaliproden 030304 developmental biology business.industry MESH: Pyridines MESH: Time Factors Magnetic resonance imaging Rat brain Mr imaging MESH: Male Rats Disease Models Animal chemistry MESH: Disease Models Animal business MESH: Alzheimer Disease 030217 neurology & neurosurgery |
Zdroj: | Investigative Radiology Investigative Radiology, Lippincott, Williams & Wilkins, 2002, 37 (6), pp.321-327. ⟨10.1097/00004424-200206000-00003⟩ Investigative Radiology, 2002, 37 (6), pp.321-327. ⟨10.1097/00004424-200206000-00003⟩ |
ISSN: | 0020-9996 |
DOI: | 10.1097/00004424-200206000-00003 |
Popis: | RATIONALE AND OBJECTIVES. The neurotrophic effect of Xaliproden has been followed using sequential cerebral magnetic resonance imaging (MRI) in rats with vincristine-induced brain lesion as a model of Alzheimer disease. METHODS. Nineteen rats received an intraseptal injection of vincristine on day 0, followed by a daily gavage with either the vehicle (Tween-20 1%) (n = 10) or Xaliproden (10 mg/kg) (n = 9). Eight sham-operated controls received a daily gavage with either the vehicle (n = 4) or Xaliproden (n = 4). Brain MR imaging was performed at 4.7 T on a Biospec 47/30 MR system before surgery then 3, 7, 10, and 14 days after surgery. RESULTS. At day 3 following vincristine injection, an increase in MR signal intensity in the septum was observed on T2-weighted images. This increase was maximal at day 10, and remained stable until day 14. Daily treatment with Xaliproden delayed the appearance of hypersignals until day 7 and reduced by Ca. 50% the magnitude of the increase in signal intensity from day 10. No changes were observed in the hippocampus. CONCLUSION. Quantitative MRI objectifies noninvasively the neuroprotective effect of Xaliproden on rat brain anatomy. |
Databáze: | OpenAIRE |
Externí odkaz: |
Pro tento záznam nejsou dostupné žádné jednotky.